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Psammoma  bodies  are  spheres  of  calcium  or  concentric  rounded  laminar  microcalciﬁca-
tions  between  5  and  100  mm  in  size.  They  are  due  to  modiﬁcations  caused  by  necrotic
phenomena.
Mammary  metastases  are  extremely  rare.  The  primary  tumours  are  melanomas,  lym-
phomas,  ovarian  and  pulmonary  carcinomas.  It  is  very  unusual  for  mammary  metastases
to  be  of  ovarian  origin:  only  a few  cases  have  been  reported  in  the  literature  [1—7]. The
ﬁrst  requirement  if  a  mammary  nodule  arises  following  ovarian  cancer  is  to  eliminate  a
primary  breast  tumour.
We  report  a  case  of  mammary  metastasis  of  an  ovarian  carcinoma.  We  will  present  the
clinical  and  paraclinical  signs  which  enable  the  diagnosis  to  be  made,  then  we  shall  discuss
the  various  treatment  possibilities.
Observation
The  patient  was  aged  36,  married,  without  children,  and  with  no  particular  history  of
disease.  She  had  consulted  3  years  previously  for  an  increase  in  abdominal  volume.  Clinical
examination  revealed  an  abdominal/pelvic  mass  reaching  the  umbilicus.  Abdominopelvic
CT  showed  a  mass  of  ovarian  origin  measuring  170/110  mm  with  moderately  abundant
ascites.  Exploratory  laparotomy  objectiﬁed  a left  ovarian  tumour  measuring  180/110  mm.
The  cancer  was  classed  as  2C  on  the  FIGO  classiﬁcation.
A  total  hysterectomy  was  performed  with  omentectomy  and  biopsy  samples  taken  from
the  parietal  peritoneum  and  the  omentum.  The  biopsy  samples  taken  showed  no  abdominal
extension.  The  extension  assessment  did  not  show  any  secondary  localisation.  The  patient
∗ Corresponding author.
E-mail address: mohcineb@yahoo.fr (H. Boufettal).
211-5684/$ — see front matter © 2011 Published by Elsevier Masson SAS on behalf of the Éditions françaises de radiologie.
oi:10.1016/j.diii.2011.11.001
ry  65
Figure 2. A histological cross-section (enlargement ×100): papil-
lary serous cystadenocarcinoma of the ovary with psammoma bodies
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underwent  six  courses  of  chemotherapy  with  cyclophos-
phamide,  Adriblastina® (doxorubicin)  and  cisplatin.  Com-
plete  remission  had  been  obtained  by  the  time  of  the
follow-up  CT.
Postoperative  recovery  was  uneventful  and  the  patient
was  discharged  from  hospital  on  day  3  following  the  pro-
cedure.  The  anatomopathological  study  showed  a  papillary
serous  cystadenocarcinoma  of  the  ovary.  Three  years  after
the  end  of  her  chemotherapy,  the  patient  presented  a  nod-
ule  in  the  superior  external  quadrant  of  the  right  breast,
measuring  2  cm  in  diameter  and  mobile  relative  to  deep  and
superﬁcial  tissue.  Examination  of  the  lymph  nodes  did  not
reveal  any  mobile  adenopathy.  Mammography  found  a highly
dense  mass  with  a  spiculated  outline,  without  microcalciﬁ-
cations  (Fig.  1)  with  an  infracentimetric  lymph  node  in  the
right  axillary  process.
An  extended  lumpectomy  was  performed,  which  objec-
tiﬁed  a  papillary  serous  cystadenocarcinoma  measuring
17  mm  exhibiting  psammoma  bodies  (Fig.  2).  The  margins  of
the  exeresis  were  healthy.  The  procedure  was  completed  by
homolateral  lymph  node  dissection  which  found  three  lymph
nodes  invaded  of  the  10  removed.  Immunohistochemistry
showed  the  absence  of  oestrogen  and  progesterone,  BCL-2
and  Her-2  receptors.  The  extension  assessment  was  normal,
comprising  a  thoracic  X-ray  and  an  abdominal,  pelvic  and
thoracic  CT  scan.  The  breast  was  subjected  to  radiotherapy,
and  the  patient  underwent  adjuvant  chemotherapy  asso-
ciating  cyclophosphamide,  Adriblastina  and  cisplatin.  After
14  months,  no  recurrence  has  been  observed.  All  in  all,  this
was  a  case  of  mammary  and  lymph  node  metastases  of  an
ovarian  cystadenocarcinoma.
Discussion
Mammary  metastases  represent  0.5  to  2%  of  the  malig-
nant  lesions  of  the  breast.  They  occur  in  the  absence  of
any  breast  cancer  risk  factor.  They  may  be  synchronous  or
metachronous  with  the  primary  tumour,  manifesting  a  few
months  or  some  years  after  discovery  of  the  primary  tumour
[1—3,8—10].  Less  than  300  cases  of  mammary  metastases
have  been  recorded  in  the  literature,  of  which  only  10  or  so
cases  are  of  ovarian  origin.  A  third  of  the  primary  tumours
Figure 1. On mammography: a highly dense mass with a spicu-
lated outline, without microcalciﬁcations.
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Iovered with barely atypical tumoral cells, with numerous spheres
f calcium, H&E (haematoxylin and eosin) stained.
f  mammary  metastases  are  melanomas  and  lymphomas
8—10].
Papillary  serous  cystadenocarcinoma  of  the  ovary  with
sammoma  bodies  is  usually  diagnosed  in  women  aged
etween  30  and  50  years  old,  but  it  can  also  be  found  in
omen  over  50.
The  prognosis  is  relatively  favourable  compared  with
erous  adenocarcinomas  without  psammoma  bodies.  Two
ypotheses  are  proposed  to  explain  the  formation  of  psam-
oma  bodies:  the  ﬁrst  is  the  formation  of  hydroxyapatite
y  tumoral  cells  in  the  process  of  necrosis,  while  the  second
s  the  effect  of  osteopontin,  which  is  a  protein  involved  in
he  mineralisation  of  bone  tissue  and  which  is  thought  to  be
roduced  by  macrophages  in  tumoral  lesions  [6].  The  greater
he  number  of  psammoma  bodies,  the  greater  the  tumoral
ecrosis  and  the  better  the  prognosis  [1].
The  anatomopathologist  should  be  informed  of  the  exis-
ence  of  the  primary  tumour.  Histology  can  generally  easily
ifferentiate  lesions  of  metastatic  origin  from  lesions  of
rimary  origin.  Unlike  primary  breast  tumours,  mammary
etastases  are  generally  well  delimited  and  seem  to  dis-
lace  the  mammary  ducts  rather  than  arise  from  them  [2,7],
hereas  in  our  case,  the  lesion  presented  a  spiculated  out-
ine.
Mammary  biopsy  shows  cells  of  different  types  and
tructure  from  those  of  mammary  tissue  with,  on
mmunohistochemical  analysis,  a  lack  of  oestrogen  and  pro-
esterone,  BCL-2  and  Her-2  receptors  [4].  It  is  difﬁcult  to
ifferentiate  between  metastasis  and  primary  cancer  of  the
reast  and  the  process  has  to  be  based  on  a  series  of  clini-
al,  radiological,  and  histological  arguments.  The  presence
f  a  primary  cancer  affecting  another  organ  and  the  his-
ological  concordance  between  the  primary  site  and  the
etastasis  usually  permits  the  decision  to  be  made  [4,5,8].
n  our  case,  it  was  possible  to  conﬁrm  the  metastatic  nature
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f  the  carcinoma  from  extemporaneous  examination  of  the
umour.
The  treatment  of  mammary  metastases  is  palliative  [3].
t  is  based  on  chemotherapy  and  surgery.  The  place  of
hemotherapy  [9]  is  still  marginal  and  uncertain  owing  to
he  rarity  of  these  metastases  and  conditions  that  are  often
omewhat  unfavourable  for  using  it.  The  protocol  most  used
s  CAP,  in  which  the  treatment  associates  cyclophosphamide,
driblastina  and  cisplatin.  It  is  administered  in  six  courses
t  3-week  intervals.  The  indications  for  surgical  treatment
f  intramammary  metastases  are,  on  the  other  hand,  con-
roversial  [2].  They  do  not  constitute  the  subject  of  any
onsensus  based  on  sufﬁciently  high  levels  of  evidence,  and
equire  multidisciplinary  agreement  of  the  various  people
nvolved  in  the  patient’s  management  (the  surgeon,  radiol-
gist,  anatomopathologist  and  radiotherapy  oncologist).
onclusion
ammary  metastases  are  extremely  rare.  Their  originat-
ng  from  the  ovary  is  exceptional,  but  this  origin  must  be
onsidered  whenever  any  malignant  lesion  of  the  breast
ccurs.  Treatment  is  palliative,  and  is  based  on  surgery  and
hemotherapy.isclosure of interest
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